Tamoxifen-induced growth of leiomyomas. A case report.
BACKGROUND
Tamoxifen, a nonsteroidal estrogen agonist-antagonist, is used in the treatment of breast cancer.


METHODS
A postmenopausal woman, aged 73, while being treated with Tamoxifen, developed continuous growth of her myomatous uterus, became symptomatic and required surgery.


CONCLUSIONS
Tamoxifen at a dose of 40 mg/d has been associated with endometrial carcinoma. The growth of myomas seen with Tamoxifen in this patient seems to be a result of its direct agonist properties.
Kang
J
J
Department of Obstetrics and Gynecology, College of Physicians and Surgeons of Columbia University, New York, New York, USA.
Baxi
L
L
Heller
D
D
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000628:therapy; D002278:Carcinoma in Situ / Q000628:therapy; D018275:Carcinoma, Lobular / Q000628:therapy; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000139:chemically induced* / Q000601:surgery; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000601:surgery
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen